Clinical Trials List
2023-08-01 - 2029-01-17
Phase III
Not yet recruiting1
Recruiting3
ICD-10C18.3
Malignant neoplasm of hepatic flexure
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9153.0
Malignant neoplasm of hepatic flexure colon
-
Trial Applicant
GlaxoSmithKline
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 黃盈慈 無
- 詹仁豪 無
- Shang-Hung Chen 無
- Peng-Chan Lin 無
- 陳柏全 無
- Po-Wen Lin 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林宗哲 無
- 梁逸歆 無
- YU-YUN SHAO 無
- 陳姿君 無
- Been Ren Lin 無
- Chih-Hung Hsu 無
- TSUNG-HAO LIU 無
- 鄭永銘 無
- 洪基翔 無
- 陳國興 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
8-12 participants
-
Global
711 participants
